MS115 是一种选择性 PRMT5/MEP50 PROTAC 降解剂(DC50 值分别为 17.4 nM 和 11.3 nM),可促进 PRMT5/MEP50 泛素化和降解,并对乳腺癌具有抗癌活性(粉色:PRMT5 和 MEP50 配体 (MS-X40590);蓝色:VHL 配体 (MS-K17554);黑色:连接子)。
产品编号: MS-M45977 CAS No.: 3109377-60-5 分子式: C63H88FN11O13S 分子量: 1258.50
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

MS115 是一种选择性 PRMT5/MEP50 PROTAC 降解剂(DC50 值分别为 17.4 nM 和 11.3 nM),可促进 PRMT5/MEP50 泛素化和降解,并对乳腺癌具有抗癌活性(粉色:PRMT5 和 MEP50 配体 (MS-X40590);蓝色:VHL 配体 (MS-K17554);黑色:连接子)。

生物实验数据

生物活性 MS115 is a selective PRMT5/MEP50 PROTAC degrader (DC50 values of 17.4 nM and 11.3 nM, respectively) that promotes PRMT5/MEP50 ubiquitination and degradation and exhibits anticancer activity against breast cancer (pink: PRMT5 and MEP50 ligand (MS-X40590); blue: VHL ligand (MS-K17554); black: linker).
体外研究
(In Vitro)

MS115 (2.1 μM; 120 min) 在无细胞实验中可抑制 PRMT5 甲基转移酶活性,其 IC50 为 2.1 μM。
MS115 (0.01-5 μM; 3-72 h) 可在 MDAMB468 细胞中以浓度和时间依赖的方式强效且选择性地降解 PRMT5 (DC50: 17.4 nM) 和 MEP50 (DC50: 11.3 nM),对两种蛋白的最大降解率均可达 85%以上。
MS115 (0.5-5 μM; 24-72 h) 可介导 MDAMB468 细胞中 PRMT5/MEP50 的降解,该过程需要同时结合 PRMT5 与 VHL,并通过泛素-蛋白酶体系统进行。
MS115 (7 d) 可抑制 MDAMB468 细胞增殖,其 gIC50 为 5.6 μM。
MS115 (serial dilutions; 5 d) 可抑制 MDAMB453、MDAMB231 和 MCF7 乳腺癌细胞的增殖,其活性与 PRMT5 抑制剂 GSKi 相当。
MS115 (0.004-5 μM; 7 h-3 d) 可在 PC-3 前列腺癌细胞中强效降解 PRMT5/MEP50,其效力优于 PRMT5 降解剂 MS4322。
MS115 (0.5-5 μM; 3 d) 可在 MCF10A 正常乳腺上皮细胞和 PNT2 正常前列腺上皮细胞中降解 PRMT5/MEP50。
MS115 (5-6 d) 可在正常上皮细胞系 (MCF10A、PNT2) 中降解 PRMT5/MEP50,且无显著细胞毒性。

Western Blot Analysis

Cell Line: MDAMB468 triple negative breast cancer cells
Concentration: 0.01-0.5 μM (72 h degradation assay); 0.5-5 μM (24 h degradation assay); 2 μM (time-dependent degradation assay)
Incubation Time: 3-48 h (2 μM time-dependent assay); 24 h (0.5-5 μM assay); 72 h (0.01-0.5 μM assay)
Result: Degraded PRMT5 with a DC50 of 17.4 nM and a maximum degradation (Dₘₐₓ) of 86.0 % after 72 h of treatment.
Degraded MEP50 with a DC50 of 11.3 nM and a Dₘₐₓ of 91.4 % after 72 h of treatment.
Induced time-dependent degradation, with PRMT5 degradation detectable by 6 h and MEP50 degradation detectable by 12 h of treatment with 2 μM MS115.
Reduced PRMT5 and MEP50 protein levels to near-undetectable levels at 0.5 μM, and eliminated detectable PRMT5 and MEP50 protein at 5 μM after 24 h of treatment.

Western Blot Analysis

Cell Line: MDAMB468 triple negative breast cancer cells (including sgVHL and sgNTC CRISPR-modified cells)
Concentration: 0.5-5 μM (72 h degradation assay); 5 μM (24 h mechanism assay with 2 h GSKi/VHL-1 pretreatment); 5 μM (24 h mechanism assay with 1 h MG132/MLN4924 pretreatment); 0.5-5 μM (24 h sgVHL/sgNTC cell assay)
Incubation Time: 72 h (0.5-5 μM degradation assay); 24 h (5 μM mechanism assays, with 1-2 h pretreatment); 24 h (0.5-5 μM sgVHL/sgNTC cell assay)
Result: Reduced PRMT5 and MEP50 protein levels to near-undetectable levels and inhibited sDMA levels after 72 h of treatment with 5 μM MS115.
Rescued PRMT5 and MEP50 degradation when cells were pretreated with GSKi or VHL-1, confirming dependence on PRMT5 and VHL binding.
Rescued PRMT5 and MEP50 degradation when cells were pretreated with MG132 or MLN4924, confirming the ubiquitin-proteasome system is required for degradation.

Cell Viability Assay

Cell Line: MDAMB468 triple negative breast cancer cells
Concentration: Serial dilutions
Incubation Time: 7 days
Result: Inhibited MDAMB468 cell proliferation with a growth inhibitory IC50 (gIC50) of 5.6 μM.

Western Blot Analysis

Cell Line: PC-3 prostate cancer cells
Concentration: 0.004-2.5 μM (7 h degradation assay); 0.5-5 μM (3 days degradation and sDMA assay)
Incubation Time: 7 h (0.004-2.5 μM assay); 3 days (0.5-5 μM assay)
Result: Degraded PRMT5 and MEP50 at concentrations lower than MS4322, with detectable degradation at 0.004 μM and near-complete degradation at 2.5 μM after 7 h of treatment.
Reduced PRMT5 and MEP50 protein levels to near-undetectable levels and inhibited sDMA levels after 3 days of treatment with 5 μM MS115.

Western Blot Analysis

Cell Line: MCF10A normal breast epithelial cells, PNT2 normal prostate epithelial cells
Concentration: 0.5-5 μM
Incubation Time: 3 days
Result: Completely degraded PRMT5 and MEP50 after 3 days of treatment with 5 μM MS115, and reduced PRMT5 and MEP50 to near-undetectable levels with 0.5 μM MS115 in MCF10A cells.
Significantly reduced PRMT5 and MEP50 protein levels after 3 days of treatment with 5 μM MS115 in PNT2 cells.

Cell Viability Assay

Cell Line: MCF10A normal breast epithelial cells, PNT2 normal prostate epithelial cells
Concentration: Serial dilutions
Incubation Time: 5 days (MCF10A cells); 6 days (PNT2 cells)
Result: Showed no significant toxicity in MCF10A cells at concentrations up to 15 μM, with cell viability remaining >100% of control at all tested concentrations.
Showed minimal toxicity in PNT2 cells, with cell viability remaining >80% of control even at the highest tested concentration.
性状 固体
颜色 White to off-white

化学信息

分子量 1258.50
分子式 C63H88FN11O13S
CAS No. 3109377-60-5

储存&溶解度

储存方式

-20°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础